Surgery boost for lung cancer drug? new trial aims to find out
NCT ID NCT07177092
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 30 times
Summary
This study looks at whether removing the main lung tumor before taking the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 118 adults with stage III-IV cancer who haven't had treatment before will be randomly assigned to get surgery plus the drug or the drug alone. The goal is to see if the combination delays cancer progression better than the drug by itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.